Aim. Prostate cancer (PCa) is the second most common nonskin malignancy and the second
most common cause of cancer‐related deaths in men. The most common site of metastasis …

Androgen deprivation therapy as single modality therapy was the standard management for
oligometastatic prostate cancer (PCa). Current paradigm shifts toward a multimodality …

BACKGROUND Early detection has increased prostate cancer (PCa) incidence.
Randomized trials have demonstrated that early detection reduces the incidence of de novo …

Background Brain metastases from prostate cancer are rare and poorly described. We
sought to assess the proportion of brain metastases arising from prostate cancer and to …

Purpose Using the Surveillance, Epidemiology, and End Results database (SEER) to
assess the incidence and risk factors of morbidity and prognosis for bone metastases in …

Metastatic prostate cancer (mPCa) is one of the leading causes of cancer-related mortality in
both the US and Europe. Androgen deprivation is the first-line therapy for mPCa; however …

Objectives To estimate the prevalence of prostate cancer with bone metastasis in Beijing,
and to estimate hospital visits and direct treatment costs among male urban employees with …

Objectives. To estimate the prevalence of unsuspected anxiety or depression in prostate
cancer patients and their spouses, as well as factors involved in its onset. Materials and …

Recently, studies on competing endogenous RNA (ceRNA) networks have become
prevalent, and circular RNAs (circRNAs) have crucial implications for the development and …

Abstract Background The CHAARTED and LATITUDE trials demonstrated improved
outcomes with docetaxel or abiraterone plus androgen deprivation therapy in metastatic …